Italy lifts ban on Novartis vaccines

By Eric Palmer The leader of the pack has come around on Novartis’ ($NVS) flu vaccines. The company said authorities in Italy have lifted a ban on a number of Novartis vaccines ...

GSK reports letdown in PhIII malaria vaccine study

By Ryan McBride In a study inspired by hope of routing malaria in African babies, GlaxoSmithKline’s ($GSK) experimental vaccine failed to live up to expectations. The experimental ...

Takeda takes aim at becoming next big vaccine developer

By Ryan McBride Takeda is wheeling and dealing in an effort to become a global player in the vaccines business, a fast-growing market dominated by the likes of GlaxoSmithKline ($GSK), ...

Switzerland, Canada clear Novartis flu vaccines after tests

With 2 bans lifted, Swiss drugmaker presses other European regulators to do the same By Tracy Staton Switzerland’s suspension of Novartis flu vaccines Agrippal and Fluad was ...

Cigarette maker Philip Morris rolls vaccine interests into China

By Ryan McBride Craving growth in the huge market for tobacco products in China, Philip Morris International ($PM) has invested in rights to flu vaccines made from a species of tobacco ...

Canada joins in on Novartis vaccine suspension

By Tracy Staton Add Canada to the growing list of countries weighing in against Novartis’ ($NVS) flu vaccines. Health Canada said it would suspend the shots, following similar ...

An Early Christmas for Flu Vaccine Companies?

By Brenton Flynn While the flu vaccination market isn’t home to many blockbuster drugs, the fact remains that it can be a very lucrative business if and when outbreaks occur. ...

Germany, France join crowd withdrawing Novartis vaccines

Authorities find no particulates but pull flu vaccines as precaution By Eric Palmer Much of the EU crowd has decided to jump on the bandwagon, pulling some of Novartis’ ($NVS) flu ...

Switzerland, Italy Ban Novartis Flu Vaccines

By MARTA FALCONI ZURICH—Switzerland’s health regulator imposed an immediate ban on Novartis AG’sNOVN.VX -0.81% flu vaccines Thursday after possibly contaminated flu ...

An Early Christmas for Flu Vaccine Companies?

By Brenton Flynn While the flu vaccination market isn’t home to many blockbuster drugs, the fact remains that it can be a very lucrative business if and when outbreaks occur. ...

Gilenya, Afinitor among bright spots in flat Novartis quarter

OTC sales falter, Diovan loses to generics, vaccines shrink–but newer meds shine By Tracy Staton When it comes to news releases, CEOs can’t control the conversation. No ...

Novartis plant delay, vaccine woes steal spotlight

By Tracy Staton Manufacturing woes, actual and potential, overshadowed Novartis’ ($NVS) earnings announcement today. In the realm of the actual, the company’s Lincoln, ...
Page 1 of 3123
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS